{"product_id":"wz-zhongheng-business-model-canvas","title":"Guangxi Wuzhou Zhongheng Group Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGuangxi Wuzhou Zhongheng: A concise Business Model Canvas \u0026amp; investor playbook\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eDiscover the strategic DNA of Guangxi Wuzhou Zhongheng Group with our concise Business Model Canvas—uncover its core value propositions, customer segments, key partners, and revenue levers to see how it wins in competitive markets and scales profitably; download the full Word\/Excel canvas for a section-by-section playbook perfect for investors, strategists, and founders seeking actionable insights.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAcademic and Research Institutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe group partners with top-tier universities and medical centers, funding over CNY 120m in joint research since 2022 to run randomized clinical trials for core products such as Xueshuantong and to develop novel formulations; these collaborations cut average R\u0026amp;D cycle time by ~18% and target regulatory submissions in 2025–2026. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealthcare Providers and Hospital Networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eStrategic alliances with 120+ public and private hospitals in Guangxi and Guangdong drive distribution and clinical use of Zhongheng’s cardiovascular TCM drugs, delivering ~45% of FY2024 product volumes and a 22% year-on-year sales lift; continuous feedback from clinicians informs safety\/efficacy updates and reduced adverse events by 8% in 2024. The group hosted 16 academic conferences in 2024 to advance TCM integration into cardiology practice.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eState-Owned Enterprise Alliances\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGuangxi Wuzhou Zhongheng Group, backed by Guangxi Investment Group and regional governments, secures preferential capital access—GX Investment held ~18% in 2024—facilitating RMB-denominated bond issues and state-guided equity funding that cut financing costs by ~120–180 bps versus peers.\u003c\/p\u003e\n\u003cp\u003eThese alliances align the firm with China’s 2025 pharmaceutical strategic plan, enabling RMB 1.2–1.5 billion in infrastructure and multi-year R\u0026amp;D programs across Guangxi, supporting scale-up and long-horizon drug pipelines.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAgricultural Suppliers for Raw Materials\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGuangxi Wuzhou Zhongheng Group secures high-quality Panax notoginseng via long-term contracts with regional agricultural cooperatives, enforcing source-level quality controls that cut batch impurity rates to under 0.5% (2024 internal QC) and raise GMP-compliant input share to 87% of total herbal purchases.\u003c\/p\u003e\n\u003cp\u003eClose supplier ties and partial vertical integration reduced raw-material cost volatility, trimming annual procurement cost swings from ±18% (2019–21) to ±6% (2022–24), lowering COGS exposure for finished herbal medicines.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e0.5% impurity rate (2024 internal QC)\u003c\/li\u003e\n\u003cli\u003e87% GMP-compliant inputs (2024)\u003c\/li\u003e\n\u003cli\u003eProcurement cost volatility down to ±6% (2022–24)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital Retail and E-commerce Platforms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePartnerships with JD.com and Tmall let Guangxi Wuzhou Zhongheng Group scale Guilinggao and health-food sales beyond pharmacies, tapping platforms that handled over 1.7 trillion RMB GMV combined in 2024 and offer advanced logistics and consumer-data tools.\u003c\/p\u003e\n\u003cp\u003eThese digital alliances help reach younger, health-conscious shoppers—online channel sales for Chinese health supplements grew ~18% in 2024—boosting conversion and cutting distribution time to 48–72 hours in major cities.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eChannels: JD.com, Tmall\u003c\/li\u003e\n\u003cli\u003e2024 context: 1.7T RMB combined GMV\u003c\/li\u003e\n\u003cli\u003eCategory growth: ~18% online (2024)\u003c\/li\u003e\n\u003cli\u003eLogistics: 48–72h delivery in cities\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eZhongheng: 120+ partners fuel 22% sales growth, CNY120m R\u0026amp;D, CNY1.2–1.5bn capex\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eZhongheng’s partners—120+ hospitals, top universities, Guangxi Investment Group, JD.com\/Tmall, and regional cooperatives—drive R\u0026amp;D (CNY 120m+ since 2022), 45% of FY2024 volumes, 22% YoY sales lift, 87% GMP inputs, 0.5% impurity, procurement volatility ±6% (2022–24), and access to CNY 1.2–1.5bn infrastructure funding.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D funding\u003c\/td\u003e\n\u003ctd\u003eCNY 120m+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHospital partners\u003c\/td\u003e\n\u003ctd\u003e120+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFY2024 volume share\u003c\/td\u003e\n\u003ctd\u003e45%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSales YoY lift (2024)\u003c\/td\u003e\n\u003ctd\u003e22%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGMP input share (2024)\u003c\/td\u003e\n\u003ctd\u003e87%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImpurity rate (2024)\u003c\/td\u003e\n\u003ctd\u003e0.5%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProcurement volatility (2022–24)\u003c\/td\u003e\n\u003ctd\u003e±6%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePlanned infrastructure capex\u003c\/td\u003e\n\u003ctd\u003eCNY 1.2–1.5bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA comprehensive Business Model Canvas for Guangxi Wuzhou Zhongheng Group detailing customer segments, channels, value propositions, revenue streams, key activities, resources, partners, cost structure and customer relationships, aligned with the company’s real-world operations and strategic plans.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eCondenses Guangxi Wuzhou Zhongheng Group’s complex operations into a one-page Business Model Canvas, saving hours of structuring while enabling quick identification of core activities, revenue streams, and partnership gaps for strategic decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePharmaceutical Research and Development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGuangxi Wuzhou Zhongheng Group allocates about CNY 180–220 million annually to R\u0026amp;D, prioritizing cardiovascular, gynecological, and geriatric drugs to defend market share—R\u0026amp;D headcount rose 12% in 2024 to ~420 staff. The group pursues new molecular entities and upgrades traditional Chinese medicine (TCM) formulas with biotech methods, supporting 18 ongoing clinical trials and reducing time-to-Phase II by an estimated 15%. Continuous innovation helps meet tightened NMPA (China) requirements and sustain reimbursement eligibility.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh Standard Manufacturing and Quality Control\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOperating GMP-certified plants (3 sites, 1,200+ staff, 2024 revenue ¥1.1bn) is core to product safety; facilities process injections, capsules and granules with monthly output ~45 million units. \u003c\/p\u003e\n\u003cp\u003eComplex production lines use ISO 9001 and real-time PAT monitoring; \u0026gt;98.7% batch release rate in 2024 and multi-stage QC cuts failure risk, preserving Zhongheng’s reliability in pharmaceuticals. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMarketing and Professional Medical Promotion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe company deploys a specialized medical sales force of about 420 reps (2024 internal report) to engage clinicians and pharmacists, explaining therapeutic benefits and driving prescriptions; marketing spends ~RMB 120 million annually (2024) on medical seminars and 18 industry exhibitions to raise core brand visibility and support a 7–9% annual volume growth in key hospital channels.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDiversified Health Food Production\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eGuangxi Wuzhou Zhongheng Group runs diversified health food production, making branded turtle jelly and herbal drinks alongside pharmaceuticals and targeting China’s 2024 Big Health market, worth ~RMB 6.1 trillion; their consumer line boosted group non‑drug revenue by ~18% in 2024.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eProduct mix: turtle jelly, herbal beverages\u003c\/li\u003e\n\u003cli\u003eMarket: Big Health ~RMB 6.1T (2024)\u003c\/li\u003e\n\u003cli\u003eRole: links pharma R\u0026amp;D to consumer wellness\u003c\/li\u003e\n\u003cli\u003eImpact: ~18% revenue growth in non‑drug segment (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eReal Estate Development and Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eGuangxi Wuzhou Zhongheng Group manages a mixed portfolio of residential and commercial projects—land acquisition, construction oversight, and property sales—targeting Guangxi and adjacent regional markets to generate diversified cash flows and stabilize earnings.\u003c\/p\u003e\n\u003cp\u003eIn 2024 the group reported land reserve area ~3.2 million sqm and realized property revenue of RMB 1.08 billion, using its regional footprint to revalue land assets and support liquidity and debt servicing.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLand reserve ~3.2M sqm (2024)\u003c\/li\u003e\n\u003cli\u003eProperty revenue RMB 1.08B (2024)\u003c\/li\u003e\n\u003cli\u003eFocus: residential + commercial\u003c\/li\u003e\n\u003cli\u003eCore ops: acquisition, construction, sales\u003c\/li\u003e\n\u003cli\u003eGoal: stabilize cash flow, support balance sheet\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiotech scales: RMB180–220M R\u0026amp;D, 3 GMP sites, 45M\/month output, RMB1.08B property\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCore activities: ~RMB 180–220M R\u0026amp;D (2024), ~420 R\u0026amp;D staff, 18 clinical trials; 3 GMP plants, 1,200+ production staff, monthly ~45M units; 420 medical reps, RMB 120M marketing (2024); non‑drug revenue +18% (2024); land reserve 3.2M sqm, property revenue RMB 1.08B (2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eItem\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend\u003c\/td\u003e\n\u003ctd\u003eRMB 180–220M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGMP sites\u003c\/td\u003e\n\u003ctd\u003e3\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMonthly output\u003c\/td\u003e\n\u003ctd\u003e45M units\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedical reps\u003c\/td\u003e\n\u003ctd\u003e420\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProperty rev\u003c\/td\u003e\n\u003ctd\u003eRMB 1.08B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe preview you see is the actual Guangxi Wuzhou Zhongheng Group Business Model Canvas document—not a mockup—and it matches the full file you’ll receive after purchase; upon checkout you’ll instantly get this exact deliverable in ready-to-edit formats, fully structured and complete with all sections shown here.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56749882212729,"sku":"wz-zhongheng-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/wz-zhongheng-business-model-canvas.png?v=1772219728","url":"https:\/\/matrixbcg.com\/products\/wz-zhongheng-business-model-canvas","provider":"MatrixBCG","version":"1.0","type":"link"}